CNTA
$28.95
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
Recent News
Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start
Centessa Pharmaceuticals (NASDAQ:CNTA) Chief Executive Officer Mario Alberto Accardi told investors at the Leerink Partners Global Healthcare Conference that the company is aiming to establish its orexin-2 agonist program as a “best-in-class” and potentially “first-in-class” set of therapies for rar
Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference
Centessa Pharmaceuticals (NASDAQ:CNTA) used remarks at a healthcare conference to highlight recent progress in its orexin agonist program and outline near-term priorities that include a Phase II update, the start of registrational studies in rare hypersomnias, and additional proof-of-concept work in
Why Centessa Pharmaceuticals (CNTA) Is Up 9.6% After Positive ORX750 Phase 2a Sleep-Disorder Data
In recent days, Centessa Pharmaceuticals has drawn attention after reporting positive Phase 2a progress for its lead orexin receptor agonist ORX750 in narcolepsy and idiopathic hypersomnia, alongside updates on its broader neurology and neuropsychiatry pipeline. This momentum has been reinforced by broad analyst support and optimism around Centessa’s early-stage portfolio, even though it still has no approved products. Next, we’ll examine how enthusiasm around ORX750’s Phase 2a results and...
Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline
One of these is not like the other.
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%
Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.